Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human RO7502175 dose-escalation study alone and with atezolizumab in advanced solid tumors
NL-OMON56405Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7502175 and atezolizumab in Non-hematologic malignancy (2 arms), sponsored by Genentech. Primary endpoints: Dose-limiting toxicities, Adverse events and 3 more. Started Feb 2024; status: recruiting.
02
Drugs
RO7502175atezolizumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON56405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56405.